Eton Pharmaceuticals Inc
ETON
Market Cap$180.85M
Close$
$-15.06
205.3% downside
Current Fair Value
205.3% downsideOvervalued by 205.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $180.85 Million |
|---|---|
| Enterprise Value | $168.39 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.04 |
| Beta | 1.31 |
| Outstanding Shares | 25,778,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -26.98 |
|---|---|
| PEG | -28.76 |
| Price to Sales | 14.3 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.48 |
| Enterprise Value to EBIT | -74.28 |
| Enterprise Value to Net Income | -37 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Eton Pharmaceuticals Inc
16 employeesEton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKIN...